SPECT/CT骨断层融合显像对肿瘤骨转移诊断价值的探究

摘要

Objective To explore the diagnostic value of SPECT/CT bone fusion imaging in detection of malignant bone metastases.Methods Totally, 158 patients suspected for bone metasis and with bone pain of unknown origin were included in this study.All cases underwent SPECT/CT bone fusion imaging after radionuclide bone scan (BS).The results of the above-mentioned examinations were compared and analyzed with chi-square test.Results 67 of 158 patients with malignant tumors were eventually diagnosed with bone metastases.The diagnostic sensitivity of BS and SPECT/CT was 86.6% and 95.5% (OR2=3.295, P=0.069), while, the specificity was 82.4% and 92.3%(OR2=4.031, P=0.045), and the accuracy was 84.2% and 93.7% (OR2=7.229, P=0.007), respectively.Conclusion Radionuclide bone scan is still the first choice for the screening of bone metastases.Owing to combine the metabolism imaging with the anatomical imaging, SPECT/CT bone fusion imaging can effectively increase the diagnostic accuracy of metastatic bone lesions in tumor patients.%目的 探究SPECT/CT骨断层融合显像在恶性肿瘤骨转移诊断中的增益价值.方法 选取158例经病理确诊的恶性肿瘤患者,均行全身骨平面显像后对可疑骨转移或不明原因骨痛部位进行SPECT/CT骨断层融合显像,然后对全身骨显像与SPECT/CT骨断层融合显像诊断结果进行比较分析.结果 158例恶性肿瘤患者最终确诊骨转移者67例,良性病变者91例.SPECT/CT骨断层融合显像诊断骨转移瘤的灵敏度(95.5%)与全身骨显像(86.6%)相比较差异无统计学意义(OR2=3.295,P=0.069),而特异性及准确性明显高于全身骨显像(OR2=4.031,P=0.045;OR2=7.229,P=0.007).结论 全身骨显像仍作为筛查骨转移瘤的首选检查方式,SPECT/CT骨断层融合显像能够同时提供代谢与解剖信息,大大提高骨转移诊断的准确性,在诊断骨转移瘤方面具有较高的增益价值.